Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 1, January-February, p. 21–26

doi: 10.17219/acem/28343

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Differential Expression of MicroRNAs in Chronic Obstructive Pulmonary Disease

Murat Kara1,A,B,C, Gamze Kirkil2,A,B,F, Serdar Kalemci3,D,E

1 Department of Medical Genetics, Faculty of Medicine, Mugla Sitki Kocman University, Turkey

2 Department of Chest Diseases, Faculty of Medicine, Firat University, Turkey

3 Department of Chest Diseases, Faculty of Medicine, Mugla Sitki Kocman University, Turkey

Abstract

Background. This study aimed to investigate the associations of miRNA with COPD patients.
Objectives. Chronic obstructive pulmonary disease (COPD) is characterized by progressive and largely irreversible airflow limitation. COPD is one of the most common causes of death globally and it is still a serious public health problem worldwide. Pathogenesis of COPD is multifactorial including genetics and environmental factors.
Material and Methods. Sixty patients who were diagnosed with COPD according to GOLD guidance and 40 controls were involved in the study. This study was separated into four groups according to GOLD guidance. miR_16, miR_17, miR_29c, miR_92, miR_125, miR_126, miR_146, miR_155, miR_181, mir_122 expressions from the total miRNAs obtained were worked on by using real time-PCR method. The p-values are calculated based on a Student’s t-test of the replicate 2^ (– Delta Ct) values for each gene in the control group.
Results. The miRNAs expressions in normal and COPD patients were found differentially. The miR-29c (p = 0.043) and -126 (p = 0.012) were found significantly different compared to control group. When their expressions are evaluated according to stage, miR-92 expression showed down regulation stage II and no change was observed in other miRNAs. miR-29c and miR-126 expressions showed significant differences in stage III and only miR-126 expression showed significant difference in stage IV.
Conclusion. These results show that miRNA evaluations may give information about the diagnosis, staging and prognosis of the disease. In this study, we demonstrated that miR-29c and -126 are essential for the development of COPD.

Key words

COPD, MicroRNAs, smoking cigarettes

References (18)

  1. Oglesby IK, McElvaney NG, Greene CM: Micrornas in inflammatory lung disease – master regulators or target practice? Respir Res 2010, 11, 148.
  2. Li LJ, Gao LB, Lv ML, Dong W, Su XW, Liang WB, Zhang L: Association between snps in pre-mirna and risk of chronic obstructive pulmonary disease. Clin Biochem 2011, 44, 813–816.
  3. Thorington P, Rios M, Avila G, Henry J, Haynes C, Pinto Pereira LM, Seemungal TA: Prevalence of chronic obstructive pulmonary disease among stable chronic disease subjects in primary care in trinidad, west indies. J Thorac Dis 2011, 3, 177–182.
  4. Xiao J, Chen YH: Micrornas: Novel regulators of the heart. J Thorac Dis 2010, 2, 43–47.
  5. Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, Fu L, Zhang L, Wang Z, Li Z: Different mirna expression profiles between human breast cancer tumors and serum. Front Genet 2014, 5, 149.
  6. Qin HB, Xu B, Mei JJ, Li D, Liu JJ, Zhao DY, Liu F: Inhibition of mirna-221 suppresses the airway inflammation in asthma. Inflammation 2012, 35, 1595–1599.
  7. Angulo M, Lecuona E, Sznajder JI: Role of micrornas in lung disease. Arch Bronconeumol 2012, 48, 325–330.
  8. Fabbri LM, Hurd SS: Global strategy for the diagnosis, management and prevention of copd: 2003 update. Eur Respir J 2003, 22, 1–2.
  9. Baraldo S, Turato G, Saetta M: Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration 2012, 84, 89–97.
  10. Huang JT, Wang J, Srivastava V, Sen S, Liu SM: Microrna machinery genes as novel biomarkers for cancer. Front Oncol 2014, 4, 113.
  11. Tomankova T, Petrek M, Kriegova E: Involvement of micrornas in physiological and pathological processes in the lung. Respir Res 2010, 11, 159.
  12. Feng MJ, Shi F, Qiu C, Peng WK: Microrna-181a, -146a and -146b in spleen cd4+ t lymphocytes play proinflammatory roles in a murine model of asthma. Int Immunopharmacol 2012, 13, 347–353.
  13. Grant JS, White K, MacLean MR, Baker AH: Micrornas in pulmonary arterial remodeling. Cell Mol Life Sci 2013, 70, 4479–4494.
  14. Polikepahad S, Knight JM, Naghavi AO, Oplt T, Creighton CJ, Shaw C, Benham AL, Kim J, Soibam B, Harris RA, Coarfa C, Zariff A, Milosavljevic A, Batts LM, Kheradmand F, Gunaratne PH, Corry DB: Proinflammatory role for let-7 micrornas in experimental asthma. J Biol Chem 2010, 285, 30139–30149.
  15. Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL: Transgenic over-expression of the microrna mir-17- 92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 2007, 310, 442–453.
  16. Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, Lehmann U, Maus UA, Nickel N, Haverich A, Hoeper MM, Golpon HA, Kreipe H, Laenger F, Jonigk D: Plexiform vasculopathy of severe pulmonary arterial hypertension and microrna expression. J Heart Lung Transplant 2012, 31, 764–772.
  17. Ezzie ME, Crawford M, Cho JH, Orellana R, Zhang S, Gelinas R, Batte K, Yu L, Nuovo G, Galas D, Diaz P, Wang K, Nana-Sinkam SP: Gene expression networks in copd: Microrna and mrna regulation. Thorax 2012, 67, 122–131.
  18. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S: Downregulation of microrna expression in the lungs of rats exposed to cigarette smoke. FASEB J 2009, 23, 806–812.